RxDoctor Payments Data

Thomas Scarborough, MD

Allergy & Immunology · Billings, MTNPI 1235194200

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 35.1% of the total. Reporting peaked in 2021 at $661 and has fallen 64.9% since, to $232 in 2025.

$3,329in general payments, 2019–2025

Across 182 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Sanofi$432
  • Pfizer$364
  • Regeneron Healthcare Solutions, Inc.$262
  • CSL Behring$183
  • GSK$159
  • plus $761 from 15 others

What the payments were for

  • Food & beverage$3,28299%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few allergy & immunology providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$35,893
Medicare patients
176
Services billed
2,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab23$86,998
XolairOmalizumab20$75,978
Spiriva RespimatTiotropium Bromide107$63,729
Fasenra PenBenralizumab11$61,092
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$58,641
Breo ElliptaFluticasone/Vilanterol43$23,602
SymbicortBudesonide/Formoterol Fumarate67$20,629
DuleraMometasone/Formoterol44$16,325
Advair HfaFluticasone Propion/Salmeterol19$10,265
Arnuity ElliptaFluticasone Furoate40$10,196
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$6,644
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$5,491
Cromolyn Sodium29$5,274
Albuterol Sulfate HfaAlbuterol Sulfate148$4,835
Pulmicort FlexhalerBudesonide12$3,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$159$92,439156 claims
AstraZenecaSymbicort, Pulmicort Flexhaler$1,169$24,00879 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Montanaon file to place this against a meaningful peer group, so we don't.

Other allergy & immunology in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →